These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. The renin-angiotensin system in the heart and vascular wall: new therapeutic aspects. Falkenhahn M; Gohlke P; Paul M; Stoll M; Unger T J Cardiovasc Pharmacol; 1994; 24 Suppl 2():S6-13. PubMed ID: 7898096 [TBL] [Abstract][Full Text] [Related]
26. Targeting the renin angiotensin system for remission/regression of chronic kidney disease. Macconi D Histol Histopathol; 2010 May; 25(5):655-68. PubMed ID: 20238303 [TBL] [Abstract][Full Text] [Related]
27. Effect of maximal reduction of angiotensin in renal fibrosis: bad news-good news from a pediatric mouse. Border WA; Noble NA Am J Kidney Dis; 2000 Apr; 35(4):773-6. PubMed ID: 10739804 [No Abstract] [Full Text] [Related]
28. Various approaches to blockade of the renin-angiotensin system: persistent renin response. Brunner HR; Nussberger J; Waeber B J Hypertens Suppl; 1990 Dec; 8(7):S149-53. PubMed ID: 2095383 [TBL] [Abstract][Full Text] [Related]
29. Angiotensin II and glomerulonephritis. Jardine AG J Hypertens; 1995 May; 13(5):487-93. PubMed ID: 7561004 [No Abstract] [Full Text] [Related]
30. Angiotensin II receptor antagonists prevent neointimal proliferation in a porcine coronary artery organ culture model. Wilson DP; Saward L; Zahradka P; Cheung PK Cardiovasc Res; 1999 Jun; 42(3):761-72. PubMed ID: 10533617 [TBL] [Abstract][Full Text] [Related]
31. The Role of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Postangioplasty Restenosis. Liu Y; Carrey Z; Aronow WS; Alaie D; Petrillo RL; Frishman WH Am J Ther; 2015; 22(4):e107-14. PubMed ID: 23782765 [TBL] [Abstract][Full Text] [Related]
32. Evolution of blockade of the renin-angiotensin system. Johnston CI; Burrell LM J Hum Hypertens; 1995 Jun; 9(6):375-80. PubMed ID: 7473513 [No Abstract] [Full Text] [Related]
33. Renin-angiotensin system and atherothrombotic disease: from genes to treatment. Jacoby DS; Rader DJ Arch Intern Med; 2003 May; 163(10):1155-64. PubMed ID: 12767951 [TBL] [Abstract][Full Text] [Related]
34. Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Ferrario CM; Strawn WB Am J Cardiol; 2006 Jul; 98(1):121-8. PubMed ID: 16784934 [TBL] [Abstract][Full Text] [Related]
35. [Renin-angiotensin system: current view]. del Río A Med Clin (Barc); 1991 Jun; 97(1):17-20. PubMed ID: 1649939 [No Abstract] [Full Text] [Related]
36. The renin-angiotensin-aldosterone system and heart failure. Sayer G; Bhat G Cardiol Clin; 2014 Feb; 32(1):21-32, vii. PubMed ID: 24286576 [TBL] [Abstract][Full Text] [Related]
37. Angiotensin II type 1 receptor blocking agents in regression of cardiac hypertrophy--how and why? Paul B; Goyal RK Indian Heart J; 2000; 52(1):19-22. PubMed ID: 10820928 [No Abstract] [Full Text] [Related]
39. Role of the tissue renin-angiotensin system in vascular remodeling and smooth muscle cell growth. Naftilan AJ Curr Opin Nephrol Hypertens; 1994 Mar; 3(2):218-27. PubMed ID: 7842273 [TBL] [Abstract][Full Text] [Related]
40. [The clinical pharmacology of angiotensin II antagonists]. Arabidze GG; Novikova LS Farmakol Toksikol; 1990; 53(2):80-6. PubMed ID: 2369961 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]